Randhawa Simrat 4

What Happened
Randhawa Simrat, EVP and Head of R&D at Dianthus Therapeutics (DNTH), exercised multiple option tranches on March 12, 2026 and sold the resulting 33,830 shares in an open-market transaction. The options exercised totaled 33,830 shares across four strikes (7,998 @ $8.44, 5,000 @ $17.88, 8,332 @ $21.77, 12,500 @ $22.07) for a combined exercise cost of $614,166. The 33,830 shares were sold the same day at $81.48 per share for gross proceeds of $2,756,468. The sale was effected pursuant to a Rule 10b5-1 trading plan.

Key Details

• Transaction date: March 12, 2026 (Form filed March 13, 2026 — timely).
• Option exercises (acquired): 7,998 @ $8.44 ($67,503); 5,000 @ $17.88 ($89,400); 8,332 @ $21.77 ($181,388); 12,500 @ $22.07 ($275,875). Total exercise payments = $614,166.
• Sale (open market): 33,830 shares @ $81.48 = $2,756,468 (gross).
• Derivative disposition entries at $0 reflect the conversion/termination of the options when exercised. Transaction code M = option exercise; S = sale.
• Notable footnotes: F1 — sale effected under a Rule 10b5-1 plan adopted Aug 14, 2025. F2–F5 — vesting schedules for the option awards (various monthly vesting schedules starting 2023–2025).
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: filing appears timely (reported period 3/12/2026, filed 3/13/2026).

Context
This was an exercise of vested options followed by an immediate open-market sale of the same shares (often described as a cashless exercise and sale). The 10b5-1 plan note indicates the sale was pre-scheduled under an established trading plan rather than an ad-hoc decision. As always, exercises plus sales are routine forms of liquidity for executives and do not on their own indicate a view about the company’s prospects.